Lumos Diagnostics Unveils Rapid FebriDx Test

Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.

Lumos Diagnostics Holdings Ltd. has announced a partnership with BARDA to support the roll-out of FebriDx, a point-of-care test that can rapidly distinguish between bacterial and non-bacterial acute respiratory infections. The test boasts a 99% negative predictive value to exclude bacterial infections and delivers results within 10 minutes from a simple fingerstick, streamlining the diagnostic process in urgent and emergency care settings.

For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.